P3-074Efficacy of immune checkpoint inhibitors in driver mutation-positive non-small lung cancer patients

Abstract Background Recent studies have reported that immune checkpoint inhibitors (ICI) are ineffective in non-small cell lung cancer (NSCLC) patients harboring the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) receptor. Methods This study was designed as a single-institute, retrospective chart review. We reviewed 103 NSCLC patients treated with an ICI regimen (Nivolumab, Pembrolizumab, and Atezolizumab) between January 2009 and November 2018 at Nagoya Medical Center. The inclusion criteria were: metastatic or recurrent NSCLC with or without a driver oncogene, normal organ function, and ECOG Performance Status (PS) 0-2. The primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS, calculated from the first day of ICI administration) and overall response rate (ORR) Results Eighty-two pts (median age, 69 years; range, 33-88) met the inclusion criteria. Among them, 13 pts had driver oncogenes (mt+) (EGFR 12, ALK 1), and 69 pts did not have driver oncogenes (mt-). ECOG-PS was 0, 1, and 2 in 27, 40, and 15 pts, respectively. Median number of regimen prior to ICI treatment was 2 (range 1-8, including EGFR-tyrosine kinase inhibitors (EGFR-TKI) and ALK inhibitors) in mt+ pts and 1 (range 0-11) in mt- pts. Programmed cell death ligand 1 (PD-L1) expression